Parkinsons Disease
Neurology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
ProthenaPrasinezumab
RegeneronALN-SNCA
Clinical Trials (2)
Total enrollment: 632 patients across 2 trials
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
Start: May 2021Est. completion: Dec 2026586 patients
Phase 2Active Not Recruiting
First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
Start: Dec 2025Est. completion: Jun 202946 patients
Phase 1Recruiting
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
8h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
8h ago
Director of Finance
CoMind
London, UK
8h ago
Electronics Engineering Manager
CoMind
London, UK
8h ago
Director of Information Technology
Zavation Medical Products
9h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 632 patients
2 companies competing in this space